key: cord-0852612-6kydscp6
authors: Sanchez-Cerrillo, I.; Landete, P.; Aldave, B.; Sanchez-Alonso, S.; Sanchez-Azofra, A.; Marcos-Jimenez, A.; Avalos, E.; Alcaraz-Serna, A.; de los Santos, I.; Mateu-Albero, T.; Esparcia, L.; Lopez-Sanz, C.; Martinez-Fleta, P.; Gabrie, L.; del Campo Guerola, L.; Calzada, M. J.; Gonzalez-Alvaro, I.; Alfranca, A.; Sanchez-Madrid, F.; Munoz-Calleja, C.; Soriano, J. B.; Ancochea, J.; Martin-Gayo, E.
title: Differential Redistribution of Activated Monocyte and Dendritic Cell Subsets to the Lung Associates with Severity of COVID-19
date: 2020-05-16
journal: medRxiv : the preprint server for health sciences
DOI: 10.1101/2020.05.13.20100925
sha: 77931cd0a42bbcc8c27bac94576a9a9a1dda5c0d
doc_id: 852612
cord_uid: 6kydscp6

The SARS-CoV-2 is responsible for the pandemic COVID-19 in infected individuals, who can either exhibit mild symptoms or progress towards a life-threatening acute respiratory distress syndrome (ARDS). It is known that exacerbated inflammation and dysregulated immune responses involving T and myeloid cells occur in COVID-19 patients with severe clinical progression. However, the differential contribution of specific subsets of dendritic cells and monocytes to ARDS is still poorly understood. In addition, the role of CD8+ T cells present in the lung of COVID-19 patients and relevant for viral control has not been characterized. With the aim to improve the knowledge in this area, we developed a cross-sectional study, in which we have studied the frequencies and activation profiles of dendritic cells and monocytes present in the blood of COVID-19 patients with different clinical severity in comparison with healthy control individuals. Furthermore, these subpopulations and their association with antiviral effector CD8+ T cell subsets were also characterized in lung infiltrates from critical COVID-19 patients. Collectively, our results suggest that inflammatory transitional and non-classical monocytes preferentially migrate from blood to lungs in patients with severe COVID-19. CD1c+ conventional dendritic cells also followed this pattern, whereas CD141+ conventional and CD123hi plasmacytoid dendritic cells were depleted from blood but were absent in the lungs. Thus, this study increases the knowledge on the pathogenesis of COVID-19 disease and could be useful for the design of therapeutic strategies to fight SARS-CoV-2 infection.

The new SARS-CoV-2 virus causing the COVID-19 (coronavirus disease 2019), has unleashed the current pandemic. Individuals infected with this pathogen can either remain asymptomatic or progress from mild to severe clinical conditions that include the acute respiratory distress syndrome (ARDS) and death. Analytical parameters such as high concentrations of IL-6 and acute phase reactants in plasma correlate with the development of severe symptoms in COVID-19

patients (1, 2) , suggesting dysregulated immune responses in these individuals. Indeed, a cytokine storm-related syndrome has been proposed as a trigger of ARDS (3, 4) and in accordance, treatments to control inflammatory cytokine signaling are being used to reduce mortality of COVID-19 patients (5, 6) . However, it is unknown whether specific subsets of innate and adaptive immune cells could be differentially contributing to a dysregulated immune response underlying the development of ARDS in COVID-19. The most recent studies indicate that immune exhaustion of effector T lymphocytes and altered humoral responses (7) (8) (9) , combined with alterations in myeloid cells like monocytes (10, 11) might be related to increased inflammation and contribute to disease progression in SARS-CoV-2 infected patients. Dendritic cells (DC) are a heterogeneous lineage of antigen presenting cells (APC), which includes different subsets of CD123 hi plasmacytoid DCs (pDC) and conventional (cDC) CD1c + and CD141 + DCs. These innate cells are critical for activation of adaptive CD4 + and CD8 + T cell responses, and are key players in the assess in depth myeloid cell populations in COVID-19 to generate new knowledge that may contribute to the development of effective specific treatments. Additionally, it is important to better understand adaptive antiviral responses potentially present in COVID-19 patients, and how they might be associated with altered myeloid cells. Recent studies suggest that exhausted CD4 + T cell responses might be dysregulated in COVID-19 patients (20), but less is known about antiviral CD8 + T cells, which could be important for virus control. Assessment of a small number of COVID-19 patients suggests that CD8 + T cells infiltrate lungs during the course of the disease, but little information is available about which specific effector subsets are recruited (9) . Therefore, an integrative view of the myeloid and lymphoid populations altered in peripheral blood and lung tissue of the patients and their association to the severity of COVID-19, is clearly needed. In the present study, we contribute to this aim by analyzing the frequencies and activation profiles of different DC and Mo subsets present in the blood of COVID-19 patients with different levels of clinical severity and by identifying cell subsets associated with protection or disease progression.

Moreover, we have characterized inflammatory Mo and DC subsets as well as effector CD8 + T lymphocytes that are specifically recruited to the lung during progressive ARDS.

Our aim is to evaluate the impact of SARS-CoV-2 infection in circulating myeloid populations.

To this end, we followed a cross-sectional study strategy (See STROBE flow chart, Fig. S1 ) and collected peripheral blood samples from a total of n=64 individuals with COVID-19 (Median age 61 (min-max, 22-89), 57% male; 95% receiving treatment) who were recruited after a median of 3 days (0-25) upon admission (Table S1 ). For comparison purposes, 22 healthy donors were included in the study (Table S1 ). To correlate particular profiles of frequencies and activation of peripheral blood inflammatory cells and the severity of the disease, we stratified our cohort of COVID-19 patients into 3 groups of mild (G1), severe (G2) and critical (G3) disease, following recently described criteria (21). Their demographic and clinical characteristics are summarized in Table S1 and Table S2 . As shown in Fig. S1 and in agreement with previous studies (2), we observed a significant and progressive decrease of PaO2/FiO2 (PaFiO2) (p<0.0001 for G1 vs G3) and increase of plasma IL-6 (p<0.0001 for G1 vs G3) and other inflammatory parameters such as Procalcitonin (PCT, p=0.0008 G1 vs G3) and C Reactive Protein (CRP, p<0.0001 G1 vs G3) that was correlated with COVID-19 severity (Fig. S1 ).

To evaluate the impact of SARS-CoV-2 infection in circulating myeloid populations, we next examined whether specific myeloid subsets could be differentially altered in the three groups of COVID-19 patients and associated with disease progression. Using a multi-color flow cytometry panel, we determined the frequencies of the following circulating myeloid cell subsets: C Mo, T Mo, NC Mo, granulocytes, CD1c + and CD141 + cDC and CD123 hi pDC (for gating strategy, see Fig. S2 ). Using a tSNE tool, we were able to observe differences in mononuclear myeloid cells distribution based on the abundance of cell populations between COVID-19 and healthy control individuals (Fig.1A left) . A more detailed analysis suggested that these changes were due to alterations on specific myeloid subsets in COVID-19 individuals (Fig.1A, right) . An individual analysis of each myeloid subset in blood showed a significant reduction of almost all circulating myeloid cell subsets when considering all COVID-19 patients (Fig. 1B) . Interestingly, certain myeloid populations were more significantly affected in the different patient subgroups. In particular, CD123 hi pDC and CD141 + cDCs were significantly diminished in the three patient groups, suggesting a disease-rather than severity-related impact on these cells (Fig. 1B) . On the other hand, the decrease of CD1c + cDCs, and C and NC Mo was more pronounced in severe G2 and critical G3 COVID-19 patients and therefore indicating an association with severity (Fig. 1B) .

In contrast, T Mo followed a completely different pattern, since they were significantly increased in mild G1 COVID-19 patients compared to healthy controls but dramatically decreased in critical G3 COVID-19 patients (Fig.1B) . Moreover, T Mo/CD1c + cDCs ratios were higher in G1 and G2 patients with less severe disease progression (Fig. S2C ). In addition, big sized CD14 -CD16 hi HLADRgranulocytes were increased in G1 and G2, but not G3 COVID-19 subgroups; and higher ratios of these cells relative to CD1c + DCs were specifically increased in severe G2 patients ( Fig.S2B-2C ). Alterations in frequencies of specific myeloid populations have been related to clinical parameters associated with COVID-19 severity (2) . Our analyses revealed that higher frequencies of circulating C, T and NC Mo (Fig. 1C ) and CD141 + cDCs (Fig. S3B ) were moderately correlated with higher levels of blood oxygenation. Importantly, depletion of C and T Mo from the blood correlated most significantly with higher plasma levels of inflammatory markers such as PCT, CRP and in the case of C and T Mo, with higher IL-6 ( Fig. 1C-D, Fig.S3A ).

Similar trends were observed for cDC (Fig. S3A) , while no significant association was observed for granulocytes (Fig. S3B ). On the other hand, depletion of inflammatory NC Mo in COVID-19 did not associate with IL-6 plasma levels (Fig.S3A ). Together, these data indicate that frequencies of C, T and NC Mo and CD1c + cDCs are preferentially reduced in the blood during severe disease progression and these populations are differentially correlated with inflammatory markers.

We next sought to determine whether the activation state of DCs and Mo subsets was different in the subgroups of COVID-19 patients. Our previous tSNE analysis involved redistribution of cell populations considering both frequencies and expression of the maturation marker CD40, which has been linked to cellular activation and the expression of IL-6 cytokine (22, 23). As shown in When CD40 expression levels were analyzed within each myeloid cell subset in total and stratified COVID-19 patients, we observed again differences associated with disease severity in some populations (Fig. 2B) . Interestingly, CD40 expression tended to be lower in all Mo subsets from G3 patients, but most significantly on T and NC Mo (Fig. 2B) . In contrast, no significant changes in CD40 expression were observed for CD1c + and CD141 + cDC, while a mild downregulation of CD40 occurred on pDC (Fig. S4A) . Remarkably, we observed no significant or weak associations of CD40 expression in cDCs or Mo subsets with plasma IL-6 and PCT levels with the frequency of these subsets in the blood (Fig.S4B-D) . Therefore, these data highlight a differential relationship of innate activation and migration between T and NC Mo versus cDC in COVID-19 patients. 3A) . In contrast, C Mo and CD1c + DCs were also enriched but made up a very low percentage of the bronchoscopy samples. No pDCs or CD141 + cDCs were found in bronchoscopy infiltrates.

In addition, analysis of paired blood and lung samples demonstrated that T and NC Mo, and CD1c + cDCs were specifically enriched in the lung (Fig. 3B ). Similar enrichment patterns were observed with granulocytes (Fig. S5D) . Importantly, myeloid cells infiltrated in the lung expressed higher levels of CD40 than their circulating counterparts (Fig.3C ). In the lung, we observed increasing expression of CD40 on C, T and NC Mo. The latter represented the myeloid cell subset expressing the highest levels of CD40 compared to CD1c + cDC as well (Fig. 3D ). In addition, levels of CD40 on NC Mo correlated with higher CRP within this group of critical COVID-19 patients (Fig. 3E ).

Together, these data indicate preferential enrichment inflammatory Mo in the lung and contrasting maturation profiles between infiltrated NC Mo compared to T Mo and CD1c + cDCs.

To better understand the contribution of CD1c + and inflammatory Mo to either disease progression or protective antiviral immunity in COVID-19 patients, we studied the presence of infiltrating effector T cells in bronchoscopy samples. We did not observe any significant increase of T cells or changes in the ratios of CD4 + /CD8 + T cells in the lung as compared to blood (Fig. S6A ).

Expression of CD38 and CXCR5 in CD8 + T cells has been previously linked to effector function and immune exhaustion during viral infections ( Fig. 4A ) (27, 28). Next we analyzed expression of these activation markers in circulating CD8 + T cells finding a significant enrichment of activated CD38 + CD8 + T cells, more significantly those that co-expressed CXCR5 in bronchoscopies from critical COVID-19 patients requiring IMV (Fig. 4B, Fig.S6B ). Of note, CD38 + CXCR5 + and CD8 + T cells was the only subset that was significantly altered compared to both paired blood in COVID-19 patients and to blood from healthy individuals (Fig.4B ). Finally, we assessed whether frequencies or activation status of inflammatory Mo and CD1c + cDCs could be associated with any of these effector CD8 + T cell subsets. Interestingly, we observed that higher ratios of All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 16, 2020. . https://doi.org/10.1101/2020.05.13.20100925 doi: medRxiv preprint inflammatory T and NC Mo/CD1c+ cDCs were negatively associated with proportions of CXCR5 + CD38 + CD8 + T cells, suggesting a detrimental role of more preferential infiltration of inflammatory Mo versus DC during disease progression (Fig. S6C ). In addition, levels of CD40 levels in T Mo but no other myeloid cells in the lung were positively associated with proportions of infiltrated CD38 + (both CXCR5 + and CXCR5 -) CD8 + T cells ( Fig. 4C; Fig. S6D ).

In this study, associations of specific Mo and DC subsets with disease progression in COVID-19 patients are established. Our results indicate that increased proportions of transitional Mo in the blood could be used as a marker of viral control or mild clinical condition in infected patients. In contrast, dramatic decrease of T and NC Mo and CD1c + DC is associated with severe clinical outcomes in COVID-19 patients. In addition, our study shows that reduction of frequencies of T and NC Mo in the blood is associated with increased IL-6, and inflammatory markers such as PCT, CRP; this reduction is also associated with the selective recruitment to the lung of these populations and CD1c + cDCs during the development of ARDS. On the other hand, increased activation of NC Mo and defective maturation of T Mo might be associated with uncontrolled inflammation in the lung and the activation of effector CD8 + T cells. Therefore, our data highlight differential involvement of myeloid cell subsets in the pathogenesis of COVID-19 disease and immunity against SARS-Co-V2 virus. Although these data provide novel cellular insights into the pathogenesis of severe COVID-19, future studies will need to focus on mechanisms responsible for these altered cellular patterns. In this regard, recent single-cell transcriptomic analyses on inflammatory infiltrates in the lung of COVID-19 patients suggest the altered expression of genes coding for proinflammatory cytokines and/or interferons-associated and interferon-stimulated proteins that have been previously associated with the activation of antibacterial innate pathways (10) .

Our data indicate that a large proportion of COVID-19 individuals from the critical G3 group developing ARDS and requiring Invasive mechanical ventilation (IMV), were superinfected with bacteria or candida at the time of sample collection. While these superinfections were mostly detected after the initiation of IMV, the majority of critical G3 COVID-19 patients exhibited high All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 16, 2020. . levels of PCT upon admission, a parameter commonly associated with bacterial infection (29) and also an indicator of inflammation and severe COVID-19 prognosis (2) . Therefore, it is possible that COVID-19 patients might be more susceptible to microbial superinfection early or during ICU treatment and this could contribute to changes in inflammation, migration and homeostasis of myeloid cells from COVID-19 patients specifically undergoing severe disease progression. If this was the case, the simultaneous activation of antiviral and antibacterial innate recognition pathways could be a potential mechanism that might contribute to uncontrolled inflammation and immune exhaustion in these individuals, similarly to what has been described in HIV + individuals coinfected with mycobacterium tuberculosis and developing immune reconstitution inflammatory syndrome (IRIS) (30). However, further research is required to specifically address this issue.

Novel information about critical cell subsets participating in the pathogenesis of COVID-19, significant sample size and the availability of healthy non-COVID-19 controls as reference group are strengths of our research. However, a number of limitations need to be discussed. This is a cross-sectional study design comparing severe COVID-19 patients, with two sets of controls: on the one hand mild/severe COVID-19 patients; and on the other hand non-COVID-19 healthy controls. Because of this cross-sectional nature any assessment of progression will require a confirmation in prospective follow-up studies. In addition, our study provides data on bronchoscopy infiltrates rather than bronchoalveolar lavage given the fragile status of COVID-19 patients with ARDS. Although bronchoscopies might not necessarily reflect the characteristics of infiltrates present in terminal bronchioles and alveoli, our data from two patients indicate that the composition of myeloid cells in the infiltrates obtained by these methods are comparable. On the other hand, our study did not directly address the protective versus detrimental function of DC during COVID-19 infection. In this sense, CD141 + cDCs are important for the priming of antiviral CD8 + T cell responses (14, 31) and are dramatically depleted from the blood in all COVID-19 patients regardless of their clinical status, but they are almost completely undetectable in bronchoscopy infiltrates from individuals developing severe ARDS. These data might support a defect on the priming, the maintenance or exhaustion of virus-specific CD8 + T cells in the lungs; however these issues must be investigated in depth. In addition, CD1c + cDCs are known to support CD4 + T cell responses and stimulate follicular helper T cells required for effective humoral antiviral adaptive immunity (13) . While it has been proposed that protection against SARS-CoV-2 might also be at least partially mediated by specific antibodies (32), the role of CD1c + DCs inducing Tfh responses in these patients has not been addressed in our study and requires further research.

To conclude, our study unveils immune cellular networks associated with control or progression of COVID-19 disease, which might be useful for early diagnosis, and the design of new more targeted and individualized treatments. Eventually, further research on these mechanisms may lead to the development of new therapeutic or preventive strategies. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 16, 2020. . https://doi.org/10.1101/2020.05.13.20100925 doi: medRxiv preprint

A total of 64 patients diagnosed with COVID-19 after testing positive for SARS-CoV-2 RNA by qPCR were included in the study. As specified in Supplemental Table 1 , 95% of patients initiated different treatments upon hospital admission. Our cohort of COVID-19 patients was stratified into 3 groups of mild (G1), severe (G2) and critical (G3) prognosis based on respiratory frequency (RF), blood oxygen saturation (StO2), partial pressure of arterial oxygen to fraction of inspired oxygen ratio (PaFiO2) and respiratory failure values as well as by following recently described criteria (21).

Blood samples were obtained for all participants and directly used for analysis without prior ficoll gradient centrifugation, to avoid the depletion of polymorphonuclear cells.

Of note, critical G3 patients from which blood (n=24) and/or bronchoscopy samples (n=23) were collected displayed 85.71% and 100% of microbial superinfection at the time of sample collection, respectively. The majority of superinfections in these patients were observed 6 days after ICU admission and IMV support (89% from blood and 100% from bronchoscopy samples) and were caused by either only bacteria (68.75% from blood and 65% from bronchoscopy samples) or only fungi (25% from blood and 30% from bronchoscopy samples) or both types of parthogens (6.25% from blood and 5% from bronchoscopy samples) (Table S2) .

Flexible bronchoscopy procedures were conducted in all ICU patients under sedation and muscle relaxation. This technique enables the visualization of the lumen and mucosa of the trachea, and also of the proximal and distal airways. Flexible bronchoscopy is indicated to evaluate pneumonia, to asses infiltrates of unclear etiology, to aspirate secretions, and to prevent development of All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 16, 2020. . atelectasis and pneumonia associated with invasive ventilation. Furthermore, in patients suspected of having pneumonia or infections, microbiological specimen can be collected with bronchial washings. Bronchial washings consist of aspirating bronchial secretions directly or after instilling physiological serum. We did not employ local anesthetic to avoid sample alterations.

Bronchoalveolar lavage can also be performed in pneumonia patients. Nevertheless, this technique entails a high risk for patients with severe respiratory failure. This is true specially for patients with high oxygen concentration requirements such as COVID pneumonia patients. Therefore, we performed bronchoalveolar lavage solely in two cases (33). Finally, the hematopoietic lung infiltrates were obtained from bronchoscopy samples diluted in 0.9% sodium chloride at a 1: 5 ratio and after three sequential centrifugations at 1500 rpm during 10 minutes. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 16, 2020. .

(pDC) were defined as Lin -HLA-DR + CD11c -CD123 hi cells (Panel II). CD14 hi CD16 -Classical (C), CD14 int CD16 + transitional (T) and CD14 low CD16 hi non-classical (NC) monocytes were defined on the basis of CD14 and CD16 expression levels. Granulocytes were identified as large CD14 lo/-CD16 hi HLADRcells. Maturation status of myeloid cells was defined based on CD40 mean fluorescence intensity (MFI). In the case of bronchoscopy samples from critical COVID-19 patients, we added anti-CD45-Pacific Orange mAbs (BioLegend) to the previously described antibody cocktails and performed an additional panel to analyze frequencies and distribution of CD3 + CD8 + and CD4 + T cell subsets defined by expression of CD38 and CXCR5 or HLA-DR, respectively. Individual and multiparametric analysis of flow cytometry data was performed using flowJo software (Tree Star) and tSNE.

Quantitative variables were represented as median and interquartile range. Statistical differences between different cell populations or between patient cohorts between was calculated using a nonparametric two-tailed Mann Whitney test, or using a Kruskal wallis test followed by a multiple comparisons, as appropriate. Significant differences of paired analyses were calculated using a two-tailed Wilcoxon matched pairs test and a Bonferroni multiple comparison correction when possible. Association between cellular and clinical parameters was calculated using nonparametric Spearman correlations. Statistical significance was set a p<0.05. Statistical analyses were performed using the GrapPad Prism 8 Sofware.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Ethics.

Princesa in the context of REINMUN-COVID and EDEPIMIC projects and it was carried out following the ethical principles established in the Declaration of Helsinki. All included patients (or their representatives) were informed about the study and gave written informed consent. Table S1 . Demographic and clinical information from study patient cohorts. Table S2 . Detection of microbial superinfection in severe and critical COVID-19 patients.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 16, 2020. .

Du Rand IA, Blaikley J, Booton R, Chaudhuri N, Gupta V, Khalid S, et al. British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE. Thorax. 2013;68 Suppl 1:i1-i44.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 16, 2020. . https://doi.org/10.1101/2020.05.13.20100925 doi: medRxiv preprint Table S1 .

Statistical significance of differences between patient groups was calculated using a nonparametric two tailed Mann Whitney test (black). Comparisons that remained significant after a (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 16, 2020. . https://doi.org/10.1101/2020.05.13.20100925 doi: medRxiv preprint included in the study or patients stratified into groups according to mild (G1), severe (SEV, G2) and critical (CRIT, G3) clinical characteristics specified in Table S1 . Statistical differences between patient groups were calculated using a non-parametric two tailed Mann Whitney test (black) or a Kruskal Wallis test followed by a Dunn´s post hoc-test for multiple comparisons (red). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 16, 2020. . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 16, 2020. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 16, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 16, 2020. Table S1 . Values present in healthy controls (HC) were included when available. Statistical significance of differences in clinical values across the study groups were calculated using a Mann Whitney or Kruskal wallis and Dunn´s post-hoc tests. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 16, 2020. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 16, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 16, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 16, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 16, 2020. . https://doi.org/10.1101/2020.05.13.20100925 doi: medRxiv preprint

Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical Characteristics of Coronavirus Disease 2019 in China. The New England journal of medicine

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors

Effective treatment of severe COVID-19 patients with tocilizumab

Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing

Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerging microbes & infections

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell host & microbe

Human dendritic cell subsets and function in health and disease. Cellular and molecular life sciences : CMLS

Immunological Fingerprints of Controllers Developing Neutralizing HIV-1 Antibodies

BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that crosspresents necrotic cell antigens

Development, Diversity, and Function of Dendritic Cells in Mouse and Human. Cold Spring Harbor perspectives in biology

Supplemental Table 1. Demographic and clinical information from study patient cohorts